17 January 2022 - Priority review expected to be granted.
CANbridge Pharmaceuticals announced today that the Chinese National Medical Products Administration (NMPA) has accepted the new drug application for CAN108 (maralixibat oral solution (Livmarli) for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.